These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 27522385)

  • 1. Current practices of Asia-Pacific cardiologists in the utilization of bioresorbable scaffolds.
    Chanana BB; Chandra P; Cheng JJ; Dick R; Gwon HC; Hiremath MS; Huan DQ; Jeamanukoolkit A; Jiang T; Kwok OH; Lim MCL; Low AF; Mathew R; Mathew SK; McClean D; Nakamura S; Nguyen M; Qiao S; Santoso T; Saxena S; Schultz C; Sengottuvelu G; Seth A; Simonton CA; Soo CS; Sudhir K; Tsai CT; Wasan U; Whelan A; Wong C; Yap YG
    Int J Cardiol; 2016 Nov; 222():832-840. PubMed ID: 27522385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absorb bioresorbable vascular scaffold: What have we learned after 5 years of clinical experience?
    Caiazzo G; Kilic ID; Fabris E; Serdoz R; Mattesini A; Foin N; De Rosa S; Indolfi C; Di Mario C
    Int J Cardiol; 2015 Dec; 201():129-36. PubMed ID: 26298354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of bioresorbable vascular scaffold Absorb BVS® in patients with stable coronary artery disease: one-year results with special focus on the hybrid bioresorbable vascular scaffolds and drug eluting stents treatment.
    Gil RJ; Bil J; Pawłowski T; Yuldashev N; Kołakowski L; Jańczak J; Jabłoński W; Paliński P
    Kardiol Pol; 2016; 74(7):627-33. PubMed ID: 26779846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [SICI-GISE Position paper: Use of Absorb BVS in clinical practice].
    Tarantini G; Saia F; Capranzano P; Cortese B; Mojoli M; Boccuzzi G; Cuculo A; Geraci S; Mattesini A; Oreglia J; Summaria F; Testa L; Berti S; Esposito G; La Manna A; Limbruno U; Marchese A; Mauro C; Tarantino F; Salvi A; Santoro G; Varbella F; Violini R; Musumeci G
    G Ital Cardiol (Rome); 2016 Oct; 17(10 Suppl 1):28S-44. PubMed ID: 27729667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioresorbable vascular scaffold in patients with complex coronary artery disease.
    Tamburino CI; Capranzano P; Longo G; Immè S; Tamburino G; Scalia M; Condorelli A; Francaviglia B; LA Manna A; Sgroi C; Grasso C; DI Salvo ME; Capodanno D; Tamburino C
    Minerva Cardioangiol; 2016 Aug; 64(4):481-6. PubMed ID: 27128353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioresorbable vascular scaffolds for the treatment of coronary artery disease: what have we learned from randomized-controlled clinical trials?
    Rizik DG; Hermiller JB; Simonton CA; Klassen KJ; Kereiakes DJ
    Coron Artery Dis; 2017 Jan; 28(1):77-89. PubMed ID: 27561169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis.
    Stone GW; Gao R; Kimura T; Kereiakes DJ; Ellis SG; Onuma Y; Cheong WF; Jones-McMeans J; Su X; Zhang Z; Serruys PW
    Lancet; 2016 Mar; 387(10025):1277-89. PubMed ID: 26825231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of a fully bioresorbable vascular scaffold in patients with coronary artery disease: design of and rationale for the ABSORB III randomized trial.
    Kereiakes DJ; Ellis SG; Popma JJ; Fitzgerald PJ; Samady H; Jones-McMeans J; Zhang Z; Cheong WF; Su X; Ben-Yehuda O; Stone GW
    Am Heart J; 2015 Oct; 170(4):641-651.e3. PubMed ID: 26386787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease: ABSORB China Trial.
    Gao R; Yang Y; Han Y; Huo Y; Chen J; Yu B; Su X; Li L; Kuo HC; Ying SW; Cheong WF; Zhang Y; Su X; Xu B; Popma JJ; Stone GW;
    J Am Coll Cardiol; 2015 Dec; 66(21):2298-2309. PubMed ID: 26471805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus-eluting Bioresorbable Vascular Scaffold Implantation in Real World and Complex Coronary Disease: Procedural and 30-day Outcomes at Two Australian Centres.
    Robaei D; Back LM; Ooi SY; Pitney MR; Jepson N
    Heart Lung Circ; 2015 Sep; 24(9):854-9. PubMed ID: 25778622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioresorbable vascular scaffolds: design, clinical trials, and current applications.
    Devito F; Zito A; Dachille A; Carbonara R; Giardinelli F; Bulzis G; Navarese EP; Scicchitano P; Gaglione A; Masi F; Ciccone MM
    Coron Artery Dis; 2016 Mar; 27(2):151-8. PubMed ID: 26717005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design principles and performance of bioresorbable polymeric vascular scaffolds.
    Oberhauser JP; Hossainy S; Rapoza RJ
    EuroIntervention; 2009 Dec; 5 Suppl F():F15-22. PubMed ID: 22100671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioresorbable vascular scaffolds for the treatment of coronary artery disease: Clinical outcomes from randomized controlled trials.
    Rizik DG; Hermiller JB; Kereiakes DJ
    Catheter Cardiovasc Interv; 2016 Nov; 88(S1):21-30. PubMed ID: 27797464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioresorbable vascular scaffolds: From patient selection to optimal scaffold implantation; tips and tricks to minimize device failure.
    Tanaka A; Jabbour RJ; Latib A; Colombo A
    Catheter Cardiovasc Interv; 2016 Nov; 88(S1):10-20. PubMed ID: 27797460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is bioresorbable vascular scaffold acute recoil affected by baseline renal function and scaffold selection?
    Gunes HM; Yılmaz FK; Gokdeniz T; Demir GG; Guler E; Guler GB; Karaca O; Cakal B; İbişoğlu E; Boztosun B
    Int J Cardiol; 2016 Dec; 224():388-393. PubMed ID: 27681252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The absorb bioresorbable vascular scaffold in coronary bifurcations: insights from bench testing.
    Džavík V; Colombo A
    JACC Cardiovasc Interv; 2014 Jan; 7(1):81-8. PubMed ID: 24332424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioresorbable vascular scaffolds for left main lesions; a novel strategy to overcome limitations.
    Miyazaki T; Panoulas VF; Sato K; Naganuma T; Latib A; Colombo A
    Int J Cardiol; 2014 Jul; 175(1):e11-3. PubMed ID: 24845788
    [No Abstract]   [Full Text] [Related]  

  • 19. Twelve-Month Outcomes With a Bioresorbable Everolimus-Eluting Scaffold: Results of the ESHC-BVS Registry at Two Australian Centers.
    Robaei D; Back L; Ooi SY; Pitney M; Jepson N
    J Invasive Cardiol; 2016 Aug; 28(8):316-22. PubMed ID: 26567454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial.
    Diletti R; Farooq V; Girasis C; Bourantas C; Onuma Y; Heo JH; Gogas BD; van Geuns RJ; Regar E; de Bruyne B; Dudek D; Thuesen L; Chevalier B; McClean D; Windecker S; Whitbourn RJ; Smits P; Koolen J; Meredith I; Li X; Miquel-Hebert K; Veldhof S; Garcia-Garcia HM; Ormiston JA; Serruys PW
    Heart; 2013 Jan; 99(2):98-105. PubMed ID: 23118346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.